Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products Salt Lake City, Utah

Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products

Lake City, Utah - January 6, 2021 - Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"),

a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced

today that, based on its preliminary internal financial reporting for the fourth quarter 2020, unaudited quarterly revenue is

anticipated to be the highest in the Company's history and to surpass analyst estimates.

estimates for the fourth quarter ranged from $24 million to $25.98 million. Quarterly revenue is anticipated to exceed the highest

estimate and to show 20-25% growth over third quarter 2020 revenue of $21.82 million.

Egan, Co-Diagnostics CEO, remarked, "We believe that the recent global surges of COVID-19 have played a large part in increased

quarter-over-quarter revenues beating analyst estimates. We are grateful to see that our diagnostic products are being used for

COVID-19 testing, and we remain committed to doing our part to stop this global pandemic."

preliminary unaudited financial information for the quarter ended December 31, 2020 above is derived from the Company's

preliminary internal financial reports and is subject to revision based on the completion of its quarter-end accounting and financial

reporting processes necessary to finalize financial statements as of and for the quarter ended December 31, 2020. There can be

no assurance that final fourth quarter results will not differ materially from these estimated results when we report the final

results for the quarter.

Co-Diagnostics, Inc.:

Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics

technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic

acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers

for use in industries other than infectious disease and license the use of those tests to specific customers.

press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes,"

"expects," "estimates," "intends," "may," "plans," "will"

and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as

they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements

in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration

of initiatives in liquid biopsy and SNP detection, (iv) use of the Company's liquid biopsy tests by laboratories, (v) capital

resources and runway needed to advance the Company's products and markets, (vi) increased sales in the near-term, (vii)

flexibility in managing the Company's balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research

and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements

are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated

or anticipated by such forward-looking statements. Readers of this press release are cautioned not to rely on any forward-looking

statements. Any forward-looking statement made by the Company in this press release is based only on information currently available

to the Company and speaks only as of the date on which it is made. The Company does not undertake any obligation to update any

forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities